CN106795155B - 一种化合物的制备方法及其纯化以用作活性药物成分 - Google Patents

一种化合物的制备方法及其纯化以用作活性药物成分 Download PDF

Info

Publication number
CN106795155B
CN106795155B CN201580053456.7A CN201580053456A CN106795155B CN 106795155 B CN106795155 B CN 106795155B CN 201580053456 A CN201580053456 A CN 201580053456A CN 106795155 B CN106795155 B CN 106795155B
Authority
CN
China
Prior art keywords
formula
compound
compounds
mixture
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580053456.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106795155A (zh
Inventor
J·普拉策克
G·加尔克
A·格鲁嫩贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51260727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106795155(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to CN202310619597.7A priority Critical patent/CN116655629A/zh
Priority to CN202310616268.7A priority patent/CN116655627A/zh
Priority to CN202310620718.XA priority patent/CN116655630B/zh
Publication of CN106795155A publication Critical patent/CN106795155A/zh
Application granted granted Critical
Publication of CN106795155B publication Critical patent/CN106795155B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580053456.7A 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分 Active CN106795155B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202310619597.7A CN116655629A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310616268.7A CN116655627A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310620718.XA CN116655630B (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179544 2014-08-01
EP14179544.3 2014-08-01
PCT/EP2015/067340 WO2016016287A1 (de) 2014-08-01 2015-07-29 Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202310619597.7A Division CN116655629A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310616268.7A Division CN116655627A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310620718.XA Division CN116655630B (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分

Publications (2)

Publication Number Publication Date
CN106795155A CN106795155A (zh) 2017-05-31
CN106795155B true CN106795155B (zh) 2023-06-16

Family

ID=51260727

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201580053456.7A Active CN106795155B (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310620718.XA Active CN116655630B (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310616268.7A Pending CN116655627A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310619597.7A Pending CN116655629A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202310620718.XA Active CN116655630B (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310616268.7A Pending CN116655627A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分
CN202310619597.7A Pending CN116655629A (zh) 2014-08-01 2015-07-29 一种化合物的制备方法及其纯化以用作活性药物成分

Country Status (31)

Country Link
US (4) US10059707B2 (enExample)
EP (2) EP3174875B1 (enExample)
JP (1) JP6818674B2 (enExample)
KR (3) KR102830206B1 (enExample)
CN (4) CN106795155B (enExample)
AR (1) AR101403A1 (enExample)
AU (1) AU2015295376C1 (enExample)
BR (1) BR112017001678B1 (enExample)
CA (2) CA2956529A1 (enExample)
CL (1) CL2017000263A1 (enExample)
CO (1) CO2017000886A2 (enExample)
DK (1) DK3174875T3 (enExample)
ES (1) ES2828704T3 (enExample)
HR (1) HRP20201800T1 (enExample)
HU (1) HUE051350T2 (enExample)
IL (1) IL250239B (enExample)
JO (1) JO3648B1 (enExample)
LT (1) LT3174875T (enExample)
MX (1) MX369467B (enExample)
MY (1) MY198066A (enExample)
PE (1) PE20170141A1 (enExample)
PL (1) PL3174875T3 (enExample)
PT (1) PT3174875T (enExample)
RS (1) RS60921B1 (enExample)
RU (1) RU2729998C9 (enExample)
SG (1) SG11201700785UA (enExample)
SI (1) SI3174875T1 (enExample)
TW (1) TWI684593B (enExample)
UA (1) UA122773C2 (enExample)
UY (1) UY36251A (enExample)
WO (1) WO2016016287A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3174875T1 (sl) * 2014-08-01 2020-12-31 Bayer Pharma Aktiengesellschaft Postopek priprave (4S)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida in njegovega čiščenja za uporabo kot aktivna farmacevtska učinkovina
CA2995905A1 (en) * 2015-08-21 2017-03-02 Bayer Pharma Aktiengesellschaft Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
EP3560922A1 (de) 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
EP3935045B1 (de) 2019-03-05 2025-05-21 Bayer Aktiengesellschaft Synthese von 4-amino-5-methyl-1h-pyridin-2(1h)-on (zwischenverbindung der synthese des mr antagonsiten finerenone) aus 2-chloro-5-methyl-4-nitro-pyridine-1-oxid über die zwischenverbindung 2-chloro-5-methyl-4-pyridinamin
KR20210135509A (ko) 2019-03-05 2021-11-15 바이엘 악티엔게젤샤프트 4-아미노-5-메틸피리돈을 제조하는 방법
CR20220161A (es) * 2019-10-17 2022-06-17 Bayer Ag Procedimiento para preparar ésteres aciloximetílicos del ácido (4s)–(4–ciano–2–metoxifenil)–5–etoxi–2,8–dimetil–1,4–dihidro–1,6–naftiridin–3–carboxílico
JP7746261B2 (ja) * 2019-10-17 2025-09-30 バイエル アクチェンゲゼルシャフト （４ｒ，４ｓ）－４－（４－シアノ－２－メトキシフェニル）－５－エトキシ－２，８－ジメチル－１，４－ジヒドロ－１，６－ナフチリジン－３－カルボキサミドを製造するための光化学法
JP7682868B2 (ja) * 2019-10-17 2025-05-26 バイエル アクチェンゲゼルシャフト ジアステレオマー酒石酸エステルによるラセミ体の分割により２－シアノエチル（４ｓ）－４－（４－シアノ－２－メトキシフェニル）－５－エトキシ－２，８－ジメチル－１，４－ジヒドロ－１，６－ナフチリジン－３－カルボキシレートを調製する方法
KR20220084101A (ko) * 2019-10-17 2022-06-21 바이엘 악티엔게젤샤프트 부분입체이성질체 타르타르산 에스테르를 사용한 라세미체 분리에 의한 2-시아노에틸 (4s)-4-(4-시아노-2-메톡시페닐)-5-히드록시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복실레이트의 제조 방법
CA3180674A1 (en) 2020-04-22 2021-10-28 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP3900722A1 (en) 2020-04-22 2021-10-27 Bayer AG Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
TW202214624A (zh) 2020-06-16 2022-04-16 德商拜耳廠股份有限公司 藉由催化不對稱漢斯（ｈａｎｔｚｓｃｈ）酯還原法進行之製備（４ｓ）－４－（４－氰基－２－甲氧基苯基）－５－乙氧基－２，８－二甲基－１，４－二氫－１，６－㖠啶－３－羧醯胺的方法
CN112237573B (zh) * 2020-10-29 2023-12-22 瑞阳制药股份有限公司 含finerenone的片剂及其制备方法
WO2022214206A1 (en) 2021-04-08 2022-10-13 Bayer Aktiengesellschaft Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
CN115340539B (zh) 2022-01-19 2024-02-27 奥锐特药业股份有限公司 制备非奈利酮及其中间体的方法
CN115340540A (zh) * 2022-01-20 2022-11-15 奥锐特药业股份有限公司 制备非奈利酮及其中间体的方法
CN114524812A (zh) * 2022-03-18 2022-05-24 湖南凯铂生物药业有限公司 1,4-二氢-1,6-萘啶化合物的晶型制备以及合成方法
US20250270184A1 (en) 2022-04-18 2025-08-28 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
EP4286368A1 (de) 2022-05-31 2023-12-06 Bayer Aktiengesellschaft Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril
WO2024075139A1 (en) * 2022-10-06 2024-04-11 Maithri Drugs Private Limited A process for preparation of finerenone and intermediates thereof
KR20250099382A (ko) 2022-11-04 2025-07-01 난징 브이케어 파마테크 씨오., 엘티디. 부분입체 이성질체 타르타르산 에스테르를 이용하여 라세미체를 분리하여 피네레논을 제조하는 방법
TW202434241A (zh) * 2022-11-23 2024-09-01 德商拜耳廠股份有限公司 第ｉ型糖尿病之慢性腎臟病治療
CN120344528A (zh) 2022-12-16 2025-07-18 拜耳公司 用于制备4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-甲酰胺的序贯的一锅合成方法
WO2024147053A1 (en) * 2023-01-03 2024-07-11 Optimus Drugs Pvt Ltd Improved process for the preparation of finerenone
CN120731206A (zh) * 2023-03-17 2025-09-30 江苏恒瑞医药股份有限公司 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法
WO2025104752A1 (en) * 2023-11-18 2025-05-22 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of (4s)4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
CN120081840A (zh) * 2023-12-01 2025-06-03 山东诚创蓝海医药科技有限公司 一种非奈利酮-马来酸共晶及其制备方法
US20250313559A1 (en) 2024-01-05 2025-10-09 Bayer Aktiengesellschaft Method of preventing or treating heart failure in a patient using (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
WO2025247801A1 (en) * 2024-05-30 2025-12-04 Bayer Aktiengesellschaft Determination of a dosage of a nonsteroidal mineralocorticoid receptor antagonist
CN119462643A (zh) * 2024-10-17 2025-02-18 河北国龙制药有限公司 一种非奈利酮单晶及其制备方法和应用
CN119019395A (zh) * 2024-10-29 2024-11-26 成都诺和晟欣生物医药有限公司 一种非奈利酮晶型ⅰ的制备方法
CN119684288A (zh) * 2024-12-18 2025-03-25 安徽先和医药研究有限公司 非奈利酮的制备方法
CN119684289A (zh) * 2024-12-18 2025-03-25 安徽先和医药研究有限公司 一种非奈利酮的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101087769A (zh) * 2004-10-15 2007-12-12 拜尔药品公司 用于治疗肥胖的联苯－4－基－羰基氨基酸衍生物的制备及用途
CN101641352A (zh) * 2007-02-27 2010-02-03 拜耳先灵制药股份公司 取代的4-芳基-1,4-二氢-1,6-萘啶酰胺和其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
US4895860A (en) * 1989-04-21 1990-01-23 American Home Products Corporation Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9914825D0 (en) 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP5254620B2 (ja) * 2004-12-03 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｂ１アンタゴニストとしての置換ピペラジン
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
US20080312209A1 (en) 2005-07-12 2008-12-18 Glaxo Group Limited Piperazine Heteroaryl Derivatives as Gpr38 Agonists
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
CN102020587A (zh) 2010-11-25 2011-04-20 大连凯飞精细化工有限公司 2-甲氧基-4-氰基苯甲醛的合成方法
SI3174875T1 (sl) * 2014-08-01 2020-12-31 Bayer Pharma Aktiengesellschaft Postopek priprave (4S)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida in njegovega čiščenja za uporabo kot aktivna farmacevtska učinkovina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101087769A (zh) * 2004-10-15 2007-12-12 拜尔药品公司 用于治疗肥胖的联苯－4－基－羰基氨基酸衍生物的制备及用途
CN101641352A (zh) * 2007-02-27 2010-02-03 拜耳先灵制药股份公司 取代的4-芳基-1,4-二氢-1,6-萘啶酰胺和其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases;Lars Barfacker et al.;《CHEMMEDCHEM》;20121231;第7卷;1385-1403 *
Synthesis and structure–activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors;Katerina Capkova, et al.;《Bioorganic & Medicinal Chemistry Letters》;20071009;第17卷;6463-6466 *

Also Published As

Publication number Publication date
CN116655627A (zh) 2023-08-29
AU2015295376A1 (en) 2017-02-16
RU2729998C2 (ru) 2020-08-13
KR102527893B1 (ko) 2023-05-02
ES2828704T3 (es) 2021-05-27
MY198066A (en) 2023-07-31
US10399977B2 (en) 2019-09-03
USRE49860E1 (en) 2024-03-05
CA3146285C (en) 2024-01-02
BR112017001678A2 (pt) 2018-07-17
JP6818674B2 (ja) 2021-01-20
CN116655629A (zh) 2023-08-29
AU2015295376B2 (en) 2019-10-03
EP3174875A1 (de) 2017-06-07
KR102830206B1 (ko) 2025-07-07
USRE49575E1 (en) 2023-07-11
LT3174875T (lt) 2020-11-25
HRP20201800T1 (hr) 2020-12-25
IL250239B (en) 2019-09-26
KR20230066477A (ko) 2023-05-15
US20170217957A1 (en) 2017-08-03
NZ728558A (en) 2023-08-25
CA3146285A1 (en) 2016-02-04
CO2017000886A2 (es) 2017-05-10
JP2017522357A (ja) 2017-08-10
EP3660015A1 (de) 2020-06-03
HUE051350T2 (hu) 2021-03-01
US10059707B2 (en) 2018-08-28
CA2956529A1 (en) 2016-02-04
SG11201700785UA (en) 2017-02-27
RU2017106602A3 (enExample) 2019-02-21
BR112017001678B1 (pt) 2024-01-16
WO2016016287A1 (de) 2016-02-04
UY36251A (es) 2016-01-29
AR101403A1 (es) 2016-12-14
AU2015295376C1 (en) 2020-07-16
PE20170141A1 (es) 2017-04-02
TWI684593B (zh) 2020-02-11
CN106795155A (zh) 2017-05-31
CN116655630A (zh) 2023-08-29
RU2017106602A (ru) 2018-09-05
KR20250108757A (ko) 2025-07-15
SI3174875T1 (sl) 2020-12-31
PT3174875T (pt) 2020-11-05
UA122773C2 (uk) 2021-01-06
RU2729998C9 (ru) 2020-10-20
MX2017001507A (es) 2017-05-23
RS60921B1 (sr) 2020-11-30
IL250239A0 (en) 2017-03-30
MX369467B (es) 2019-11-08
DK3174875T3 (da) 2020-11-16
CN116655630B (zh) 2025-12-16
TW201619155A (zh) 2016-06-01
PL3174875T3 (pl) 2021-01-25
EP3174875B1 (de) 2020-08-19
KR20170040278A (ko) 2017-04-12
CL2017000263A1 (es) 2017-09-29
JO3648B1 (ar) 2020-08-27
US20190127369A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CN106795155B (zh) 一种化合物的制备方法及其纯化以用作活性药物成分
JP6824247B2 (ja) （４ｓ）−４−（４−シアノ−２−メトキシフェニル）−５−エトキシ−２，８−ジメチル−１，４−ジヒドロ−１，６−ナフチリジン−３−カルボキサミドの調製方法および医薬品有効成分として使用するためのその精製方法
HK1234397B (en) Method for the preparation of a compound and the purification thereof for use as an active pharmaceutical ingredient
HK1234397A1 (en) Method for the preparation of a compound and the purification thereof for use as an active pharmaceutical ingredient
NZ728558B2 (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
HK1251565B (zh) 用於制备(4s)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2，8-二甲基-1，4-二氢-1，6-萘啶-3-甲酰胺的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1234397

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant